An interventional study of Sutureless Superior Conjunctival Autograft (CAG) and Sutureless Inferior Conjunctival Autograft (CAG) in Pterygium of Both Eyes and Conjunctival Autograft, sponsored by Fayoum University. Completed at 1 site in Egypt. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Fayoum University · Not applicable, Interventional, and Treatment
Superior bulbar conjunctival autograft is the standard procedure to reduce recurrence after pterygium excision. However, harvesting superior conjunctiva causes tissue scarring, which may compromise the site for potential future glaucoma filtering surgeries. This study evaluates whether harvesting a sutureless autograft from the inferior bulbar/forniceal conjunctiva provides comparable graft stability, pain levels, and recurrence rates while preserving the superior conjunctiva.
109 studies on the registry are indexed under Pterygium; 9 are open to participants now.
This study's enrollment of 90 is above the median of 60 across 93 interventional studies indexed under Pterygium.
Browse Pterygium studies →Fayoum University is the lead sponsor of 148 studies on the registry; 44 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pterygium excision followed by preparation and placement of a sutureless autograft harvested from the superior limbal/bulbar conjunctiva.
Other: Sutureless Superior Conjunctival Autograft (CAG)
Pterygium excision followed by preparation and placement of a sutureless autograft harvested from the infronasal/inferior bulbar conjunctiva.
Other: Sutureless Inferior Conjunctival Autograft (CAG)
Following local anesthesia with topical proparacaine 0.5% and subconjunctival 2% lidocaine infiltration, standard surgical excision of the primary pterygium head and body is performed along with meticulous clearance of corneal and scleral bed fibrovascular tissue. A thin, donor conjunctival autograft matching the dimensions of the bare scleral bed (measured via surgical calipers) is harvested from the superior limbal/bulbar conjunctiva, incorporating limbal stem cell tissue. The graft is transferred to the recipient site maintaining correct orientation (limbus-to-limbus). Fixation is achieved suturelessly without the use of synthetic sutures. Pressure is applied over the graft for 5 to 10 minutes to ensure firm apposition prior to monocular eye patching.
Also known as: conjunctival autograft
Following local anesthesia with topical proparacaine 0.5% and subconjunctival 2% lidocaine infiltration, standard surgical excision of the primary pterygium head and body is performed along with meticulous clearance of corneal and scleral bed fibrovascular tissue. A thin, donor conjunctival autograft matching the dimensions of the bare scleral bed (measured via surgical calipers) is harvested from the infronasal / inferior bulbar and forniceal conjunctiva, deliberately sparing the entire superior bulbar conjunctiva for potential future ocular surgeries. The graft is transferred to the recipient site maintaining correct limbus-to-limbus orientation. Fixation is achieved suturelessly without the use of synthetic sutures. Pressure is applied over the graft for 5 to 10 minutes to ensure firm apposition prior to monocular eye patching.
Pterygium Recurrence Rate
Presence of fibrovascular tissue regrowth crossing the corneo-limbal junction onto the clear cornea .
Time frame: Evaluated at 6 months postoperatively
Graft Stability and Adherence
Evaluated on slit-lamp examination as stable, partially displaced, fully displaced, retracted, or lost.
Time frame: Evaluated on Day 1, Week 1, Month 1, Month 3, and Month 6
Postoperative Pain Levels
Patient self-reported pain score assessed on a standardized 10-point Visual Analog Scale (VAS) (0 = No Pain, 10 = Worst Possible Pain).
Time frame: Day 1, Week 1, and Month 1 postoperatively
operative time
time spent at surgery from local anaesthesia injection to graft placement
Time frame: at surgery
donor site healing
evaluated on slit lamp as time needed for the donor site to achieve complete healing
Time frame: Day 1, Week 1, and Month 1 postoperatively
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Jan 2026, 8 months.
Of 18 interventional studies with no phase under Pterygium, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 28. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.